Title : Resurrection of PARP Inhibitors in Breast Cancer.

Pub. Date : 2018 Sep

PMID : 30181424






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 A number of PARPi are currently undergoing clinical evaluation in breast cancer, with olaparib and talazoparib having demonstrated superior efficacy compared with standard chemotherapy in advanced germline BRCA-mutated cancer. talazoparib BRCA1 DNA repair associated Homo sapiens